Clinical trials: AD
Mild Cognitive Impairment (MCI), Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease
Mindfulness for Cognition in Early-stage Alzheimer's Disease
The goal of this clinical trial is to learn if mindfulness meditation can improve outcomes in older adults with and without cognitive impairment. The main questions it aims to answer are: 1.
- Conditions
- Mild Cognitive Impairment (MCI), Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease, TBI (Traumatic Brain Injury), Aging
- Trial name
- NCT06792877
- Testing
- Mindfulness Intervention, Waitlist then mindfulness
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- VA Boston Healthcare System
Health Adult Subjects, Atopic Dermatitis (AD)
Study of HXN6005 in Healthy Participants and Patients With Moderate-to-Severe Atopic Dermatitis
This is a Phase I/II, multicenter, randomized, double-blind, placebo-controlled study evaluating HXN6005 in healthy participants and patients with moderate-to-severe atopic dermatitis (AD).
- Trial name
- NCT07782476
- Testing
- HXN6005
- Where
- China
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Helixon Biotechnology (Suzhou) Co., Ltd
Logopenic Progressive Aphasia, Primary Progressive Aphasia
Targeting Language-specific and Executive-control Networks With Transcranial Direct Current Stimulation in Logopenic Variant PPA
AD afflicts over 5.5. million Americans and is one of the most expensive diseases worldwide. In AD the variant in which language functions are most affected are referred to as 'logopenic variant Primary Progressive Aphasia'…
- Trial name
- NCT03887481
- Testing
- High-definition active tDCS (HD-tDCS) + "Repeat After Me" (RAM) Treatment
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Atopic Dermatitis
AD Treatment Optimization With Ebglyss in Real-World Practice: A Multicenter Study of Patient-Centered Outcomes
The goal of this Phase 4 clinical study is to learn how Ebglyss (lebrikizumab) works and how it is dosed in everyday dermatology care for adults and adolescents (age 12 and older) with moderate-to-severe atopic dermatitis…
- Trial name
- AD-TEMPO (NCT07856134)
- Testing
- Lebrikizumab-lbkz
- Where
- 10 sites in United States
- Volunteers
- 250 people
- Sponsor
- Forefront Dermatology S.C
Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease
A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation
This trial was a multi-center, double-blind, placebo-controlled, randomized study to evaluate the efficacy and safety of AXS-05 compared to placebo for the treatment of agitation associated with Alzheimer's disease.
- Conditions
- Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation
- Trial name
- ADVANCE-2 (NCT05557409)
- Testing
- AXS-05
- Where
- 55 sites in United States, Puerto Rico
- Volunteers
- 408 people
- Sponsor
- Axsome Therapeutics, Inc.
Alzheimer Disease (AD), Mild Cognitive Impairment (MCI)
Use of a Mobile Brain-Body Imaging Approach to Evaluate the Effects of Rhythmic Auditory Stimulation on Gait and Brain Function in Alzheimer's Disease
Alzheimer's Disease (AD) is associated with impairments in both gait and cognition, significantly increasing fall risk. Falls are a leading cause of injury-related disability in older adults, and individuals with AD experience a…
- Trial name
- NCT07659964
- Testing
- Metronome
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Boston University Charles River Campus
Atopic Dermatitis
Evalution the Safety and Efficacy in Atopic Dermatitis Patients
A multi-center, open, long-term follow-up study to evaluate the efficacy and safety of FURESTEM-AD inj. in patients with moderate to severe chronic atopic dermatitis: 5-year results from the K0102 extension study
- Trial name
- NCT03962387
- Testing
- Not applicable(observational study)
- Where
- South Korea
- Volunteers
- 98 people
- Sponsor
- Kang Stem Biotech Co., Ltd.
PYY, Ghrelin
The Effect of Breakfast With Different Macronutrient Composition on PYY, Ghrelin, GLP-1,Glucose Level, VAS for Hunger, VAS for Satiety and Ad Libitum Intake 4 Hours After Breakfast in Obese Women
Gut hormones, such as PYY and ghrelin, are associated with appetite control and obesity. Protein is thought to be the most satieting nutrient and could affect production of several gut hormones.
- Conditions
- PYY, Ghrelin, Appetite, Gut Hormones
- Trial name
- NCT03697486
- Testing
- diet with different composition
- Where
- Indonesia
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Universitas Indonesia
Alzheimer's Disease
Safety and Efficacy of Donepezil in Mild to Moderate Alzheimer's Disease
This study will evaluate the safety and Efficacy of donepezil in treatment of AD patients in China.
- Trial name
- STDMMAD (NCT02787746)
- Testing
- Donepezil
- Where
- China
- Volunteers
- 241 people
- Sponsor
- Beijing Friendship Hospital
Alzheimer's Disease
Safety Study of MT-4666 in Subjects With Alzheimer's Disease
The objective of this study is to evaluate the safety and efficacy of 2 fixed dose of MT-4666 administered once daily for 52 weeks with or without receiving a concomitant acetylcholinesterase inhibitors (AChEIs), in patients with…
- Trial name
- NCT02327182
- Testing
- MT-4666
- Where
- Japan
- Volunteers
- 117 people
- Sponsor
- Tanabe Pharma Corporation
Atopic Dermatitis
A Study to Assess the Efficacy and Safety of Dupilumab in Participants With Severe Atopic Dermatitis (AD) That Are Not Controlled With Oral Cyclosporine A (CSA) or for Those Who Cannot Take Oral CSA Because it is Not Medically Advisable
The main objective of the trial is to evaluate the efficacy of 2 dose regimens of dupilumab compared to placebo, administered with concomitant topical corticosteroids (TCS), in adult patients with severe AD who are not adequately…
- Trial name
- NCT02755649
- Testing
- Dupilumab
- Where
- 73 sites in Austria, Belgium and 8 more
- Volunteers
- 325 people
- Sponsor
- Regeneron Pharmaceuticals
Atopic Dermatitis
A Clinical Study of AK120 in Adolescents With Moderate-to-severe Atopic Dermatitis (AD)
This is a A multicenter, open label, phase II clinical study to evaluate the safety, pharmacokinetics (PK), pharmacodynamics(PD), and preliminary efficacy of AK120 in adolescents with moderate-to-severe atopic dermatitis
- Trial name
- NCT06756126
- Testing
- AK120
- Where
- 6 sites in China
- Volunteers
- 24 people
- Sponsor
- Akeso
Atopic Dermatitis
A Clinical Trial to Compare Topical Agents in Adults With Mild to Moderate Atopic Dermatitis (AD)
An Explorative Clinical Trial to Evaluate an Intra Patient Comparison Design of Topical Agents in Adults with Mild to Moderate Atopic Dermatitis.
- Trial name
- NCT02376049
- Testing
- Pimecrolimus cream, Betamethasone dipropionate cream, Clobetasol propionate cream
- Where
- 2 sites in Canada, Israel
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- LEO Pharma
Mild Cognitive Impairment, Alzheimer Dementia (AD)
Closed-Loop Brain Stimulation as a Potential Intervention for Cognitive Decline
The goal of this clinical study is to investigate the effectiveness of non-invasive stimulation to enhance cognitive control abilities in older adults with and without cognitive impairment.
- Trial name
- NCT05907343
- Testing
- Closed-loop TBS, Open-loop TBS
- Where
- United States
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- University of Texas at Austin
BPH, Nocturia
Use of Autologous Adipose-Derived Stem/Stromal Cells (AD-cSVF) in Symptomatic Benign Prostate Hypertrophy
Benign prostate hypertrophy (BPH) and inflammation are common non-cancerous enlargement of the prostate, which result in urinary interference and incomplete drainage of the bladder.
- Conditions
- BPH, Nocturia, BPH With Urinary Obstruction, Prostatism
- Trial name
- SVF-BPN (NCT02961114)
- Testing
- Microcannula Harvest Adipose, Centricyte 1000, IV Sterile Normal Saline
- Where
- 2 sites in United States
- Sponsor
- Robert W. Alexander, MD, FICS
Alzheimer Disease
Efficacy and Safety of MMFS in Early AD
This study is designed to evaluate the safety and efficacy of MMFS for improving cognition and global function in patients with probable Early Alzheimer's disease.
- Trial name
- NCT03531684
- Testing
- MMFS-205-SR
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Neurocentria, Inc.
Mild Cognitive Impairment (MCI), Dementia
An Insole and Ankle Device for Monitoring Cognitive Decline in Individuals at Risk for Alzheimer's Disease and/or Alzheimer's Disease Related Dementias (AD/ADRD)
This study tests an innovative system and service for collecting objective, consistent, and in-community gait parameters suitable for use as AD/ADRD biomarkers.
- Trial name
- NCT07127133
- Testing
- Insole and ankle device
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- HealthPartners Institute
Atopic Dermatitis
Study of Generic Pimecrolimus Cream, 1% in the Treatment of Mild to Moderate Atopic Dermatitis
This is a Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple-Site Study to Evaluate the Therapeutic Equivalence of a Generic Pimecrolimus Cream, 1% (Glenmark Pharmaceuticals Ltd) to the Marketed Product…
- Trial name
- NCT02896101
- Testing
- Pimecrolimus Cream, 1%, Elidel® (pimecrolimus) Cream
- Where
- 27 sites in United States
- Volunteers
- 755 people
- Sponsor
- Glenmark Pharmaceuticals Ltd. India
Atopic Dermatitis, Atopic Dermatitis (AD)
Herbal Ointment in Treating Atopic Dermatitis Topically
Atopic dermatitis (AD), also known as atopic eczema, is a chronic inflammatory skin disorder. The current first-line recommended treatment for AD is the use of emollients, topical corticosteroids (TCS), and oral antihistamines if…
- Conditions
- Atopic Dermatitis, Atopic Dermatitis (AD), Atopic Dermatitis (Eczema), Atopic Dermatitis Eczema
- Trial name
- NCT06850311
- Testing
- herbal ointment
- Where
- Taiwan
- Volunteers
- 66 people
- Sponsor
- En Chu Kong Hospital
Atopic Dermatitis
SAR231893-LPS15497- "Dupilumab Effect on Sleep in AD Patients"
Primary Objective: To evaluate the effect of dupilumab on sleep quality in adult participants with moderate to severe atopic dermatitis (AD).
- Trial name
- NCT04033367
- Testing
- Dupilumab
- Where
- 42 sites in United States, Australia and 8 more
- Volunteers
- 188 people
- Sponsor
- Sanofi